US asthma prophylaxis approval revives Acton's interest in Aerospan alliances
This article was originally published in Scrip
Executive Summary
Acton Pharmaceuticals, a private US company that specialises in getting difficult new inhaled drug formulations onto the market, won its first supplemental new drug application (sNDA) approval from the US FDA for Aerospan (flunisolide HFA, 80mcg) Inhalation Aerosol as a prophylactic asthma maintenance therapy for adult and paediatric patients aged six and older.